spacer
home > ebr > summer 2017 > revolution or evolution?
PUBLICATIONS
European Biopharmaceutical Review

Revolution or Evolution?

Over the last 5-10 years, the biopharmaceutical industry predicted that the development of biosimilars would revolutionise the field of biologics by offering low-cost alternatives for many of these innovative therapies across multiple therapeutic areas. For example, when the Biologics Price Competition and Innovation Act was signed into law in the US as a subsection of the Affordable Care Act in 2010, it was accompanied by expectations of significant cost savings for both patients and the healthcare system. The expected savings over 10-15 years ranged from $25 billion to $250 billion, as put forth by the Congressional Budget Office and Express Scripts respectively (1).

The reality, however, is that the biosimilars market has developed much slower than expected – today, there are only three biosimilars approved in the US and 22 in the EU. To compete in the marketplace, biosimilars must be manufactured more efficiently to realise competitive pricing compared to their off-patent reference biologic. Developing these therapies is extremely challenging because they are required to have the same structure, activity and clinical efficacy and safety profile as the reference biologic, which adds significant complexity to the process.

Moreover, as the competition increases among biosimilars targeting the same reference biologic, companies are under further pressure to attain lower costs and maximise manufacturing flexibility. The high expenses associated with development therefore pose a significant hurdle for biosimilars manufacturers, who must compete on price.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Guillaume Plane is the Global Development and Marketing Manager for Merck's Biodevelopment Services. He joined the company in 2012, bringing over 15 years of biotechnology experience spanning multiple specialities. Guillaume also serves as Visiting Professor at ESCP Europe, Toulouse Business School and IONIS School of Technology and Management. He received a master’s degree in biology and health from the University of Bordeaux, France, and an additional master’s degree in innovation and entrepreneurship from ESCP Europe. 
spacer
Guillaume Plane
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement